RxDoctor Payments Data

Christopher Johnson, MD

Cardiovascular Disease · Bremerton, WANPI 1215952247

Payments from drug & device makers

$546in general payments, 2019–2025

Across 23 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$167
  • Novartis$93
  • Abiomed$57
  • Kestra Medical Technology Services, Inc.$44
  • Heartflow, Inc.$36
  • Atricure, Inc.$28
  • plus $120 from 7 others

What the payments were for

  • Food & beverage$546100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$546 in reported general payments places this provider in the 40th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$361,679
Medicare patients
1,938
Services billed
4,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis12$311,198
EliquisApixaban236$269,141
XareltoRivaroxaban206$239,613
EntrestoSacubitril/Valsartan123$169,930
JardianceEmpagliflozin103$132,404
FarxigaDapagliflozin Propanediol35$30,391
Repatha SureclickEvolocumab19$29,099
Repatha PushtronexEvolocumab15$9,784
Metoprolol Succinate599$8,261
Praluent PenAlirocumab12$6,655
Potassium Chloride119$4,117
Eplerenone37$3,828
Atorvastatin Calcium372$3,033
Losartan Potassium240$2,521
Flecainide Acetate61$2,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$19$580,339248 claims
Johnson & JohnsonXarelto$167$239,613206 claims
NovartisEntresto$93$169,930123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Bremerton

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →